Exploiting genetic and environmental vulnerabilities to target DHODH in CNS tumors
Eli E Bar1,2, Julie-Aurore Losman3,4,5
1University of Maryland, Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.
Abstract:
This review explores innovative therapeutic strategies for treating central nervous system (CNS) tumors by targeting their unique metabolic dependencies. This approach marks a significant departure from traditional cytotoxic treatments, focusing instead on the metabolic vulnerabilities created by the tumor's microenvironment and genetic profile. A key area of interest is the de novo pyrimidine synthesis pathway, which is crucial for DNA and RNA synthesis, DNA repair, and protein glycosylation. We highlight the potential of dihydroorotate dehydrogenase (DHODH) inhibitors, which have shown promising anti-tumor activity in preclinical models. The blood-brain barrier, while a challenge for drug delivery, may enhance the efficacy of these inhibitors by maintaining a unique metabolic environment in the brain. Specific brain tumors, such as glioblastoma multiforme, MYC-amplified medulloblastoma, and IDH mutant gliomas, exhibit heightened sensitivity to DHODH inhibition. We suggest that the unique metabolic environment of the brain could make DHODH a more effective therapeutic target for brain tumors compared to other cancer types. Despite the speculative nature of these findings, the compelling preclinical data warrant further investigation into brain-penetrant DHODH inhibitors for CNS malignancies.
Insights
Targeting cancer cell metabolism offers new hope for brain tumors. Dihydroorotate dehydrogenase (DHODH) inhibitors show promise by exploiting tumor metabolic vulnerabilities, especially within the unique brain environment.
Area of Science:
- Oncology
- Neuroscience
- Metabolic pathways
Background:
- Central nervous system (CNS) tumors present treatment challenges due to their unique microenvironment and genetic makeup.
- Traditional cytotoxic therapies have limitations; novel strategies targeting tumor-specific metabolic dependencies are emerging.
- The de novo pyrimidine synthesis pathway is vital for cancer cell proliferation and survival.
Purpose of the Study:
- To review innovative therapeutic strategies for CNS tumors by targeting metabolic vulnerabilities.
- To explore the potential of dihydroorotate dehydrogenase (DHODH) inhibitors as a novel treatment approach.
- To assess the feasibility of DHODH inhibition in specific brain tumor types.
Main Methods:
- Review of preclinical data on DHODH inhibitors in CNS tumor models.
- Analysis of the role of the de novo pyrimidine synthesis pathway in brain tumors.
- Consideration of the blood-brain barrier's impact on drug efficacy.
Main Results:
- DHODH inhibitors demonstrate promising anti-tumor activity in preclinical models.
- Specific brain tumors like glioblastoma multiforme, MYC-amplified medulloblastoma, and IDH mutant gliomas show sensitivity to DHODH inhibition.
- The brain's unique metabolic environment may enhance DHODH inhibitor efficacy.
Conclusions:
- DHODH inhibition represents a promising therapeutic strategy for CNS malignancies.
- The brain's metabolic context may render DHODH a more effective target for brain tumors than other cancers.
- Further investigation into brain-penetrant DHODH inhibitors for CNS tumors is warranted.
